# The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients

> **NCT01186471** · EARLY_PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 32 (actual)

## Conditions studied

- Schizophrenia
- Cognition Disorders

## Interventions

- **OTHER:** A643 (nicotine)
- **OTHER:** A643 (nicotine)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01186471
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** —
- **Final completion:** 2011-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01186471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01186471, "The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01186471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*